Vasocon-a

   
Google
 
Web NewDrugInformation.com

Vasocon-a


Drug - Vasocon-a
The trade name of the product as shown on the labeling.

Dosage - SOLUTION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Antazoline Phosphate; Naphazoline Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - 0.5%;0.05%
The potency of the active ingredient(s), Antazoline Phosphate; Naphazoline Hydrochloride. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Vasocon-a. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 018746
The FDA assigned number to Vasocon-a. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Vasocon-a. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jul 11, 1994
The date Vasocon-a was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Vasocon-a. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - OTC
The group or category of approved drugs Vasocon-a is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Vasocon-a.

Vasocon-a